Pacira Pharmaceuticals, Inc. Reports Second Quarter 2018 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. GOOGL
6. APGE
7. USO
8. HOOD
9. DFTX
10. IBM

Go back to Pacira Pharmaceuticals, Inc. Reports Second Quarter 2018 Financial Results

Pacira Pharmaceuticals (PCRX) PT Raised to $40 at BMO Capital

August 3, 2018 6:57 AM EDT

BMO Capital raised its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $40.00 (from $34.00) while maintaining a Market Perform rating.

Analsyt Gary Nachman commented, "PCRX reported 2Q18 non-GAAP revenue of $81mmabove BMO/consensus $77mm/$76mm, and EPS of $0.24 above BMO/consensus $0.09/$0.07. Solid 2Q... More

Pacira Pharma (PCRX) Tops Q2 EPS by 17c, Beats on Revenues; Offers FY18 Revenue Outlook Above Consensus

August 2, 2018 8:14 AM EDT

Pacira Pharma (NASDAQ: PCRX) reported Q2 EPS of $0.24, $0.17 better than the analyst estimate of $0.07. Revenue for the quarter came in at $80.43 million versus the consensus estimate of $78.86 million.

Second Quarter 2018 Financial Results

EXPAREL net product sales were $80.4 million in the second quarter of 2018, a 15% increase over the $69.8 million reported for the second quarter of 2017. Total operating expenses were $77.6 million in the second quarter of 2018, compared to $86.7 million in the second quarter of 2017. GAAP net income was $2.6 million, or $0.06 per share (basic and diluted), in the second... More